Curtailing Overexpression of E2F3 in Breast Cancer Using siRNA (E2F3)-Based Gene Silencing

Archives of Medical Research

Volumn 43, Issue 6, 2012, Pages 415-422

  Vimala, Karuppaiya ^a   Sundarraj, Shenbagamoorthy ^a   Sujitha, Mohanan V ^a   Kannan, Soundarapandian ^a  

^a BHARATHIAR UNIVERSITY   (India)

Author keywords

Breast cancer; E2F3 transcription factor; Overexpression; RT PCR; SiRNA

Indexed keywords

SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR E2F3A; TRANSCRIPTION FACTOR E2F3B; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BASE SEQUENCE; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; DNA PRIMERS; E2F3 TRANSCRIPTION FACTOR; FEMALE; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 84867853622     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.08.009     Document Type: Article

References (26)

1. Lu Y., Yi Y., Liu P., et al. Common human cancer genes discovered by integrated gene-expression analysis. PLoS ONE 2007, 2:1149-1158.
2. Kort J.E., Farber L., Tretiakova M., et al. The E2F3-oncomir-1 axis is activated in Wilms' tumor. J Cancer Res 2008, 68:4034-4038.
3. Skariyachan S., Krishnan R., Biradar U.B. In silico investigation and docking studies of E2F3 tumour marker: discovery and evaluation of potential inhibitors for prostate and breast cancer. Int J Pharmacol Sci Drug Res 2010, 2:254-260.
4. Olsson A.Y., Feber A., Edwards S., et al. Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. Oncogene 2007, 26:1028-1037.
5. Feber A., Clark J., Goodwin G., et al. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 2004, 23:1627-1630.
6. Oeggerli M., Tomovska S., Schraml P., et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 2004, 23:5616-5623.
7. Foster C.S., Falconer A., Dodson A.R., et al. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 2004, 23:5871-5979.
8. Knowles M.A. What we could do now: molecular pathology of bladder cancer. Mol Pathol 2001, 54:215-221.
9. WHO World Health Report 2003 2003, World Health Organization, Geneva.
10. Wang Y., Liu S., Zhang G., et al. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 2005, 7:221-229.
11. Leone G.F., Nuckolls S., Ishida M., et al. Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins. Mol Cell Biol 2000, 20:3626-3632.
12. Adams M.R., Sears F., Nuckolls G., et al. Complex transcriptional regulatory mechanisms control expression of the E2F3 locus. Mol Cell Biol 2000, 20:3633-3639.
13. Chong J.L., Tsai S.Y., Sharma N., et al. E2F3a and E2F3b contribute to the control of cell proliferation and mouse development. Mol Cell Biol 2009, 29:414-424.
14. Mcmanus M.T., Sharp P.A. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002, 3:737-747.
15. 2α in nonsmall cell lung cancer cells. J Cancer Res Clin Oncol 2012, 138:827-835.
16. Sundarraj S., Thangam R., Sreevani V., et al. γ-Sitosterol from Acacia nilotica L. induces G2/M cell cycle arrest and apoptosis through c-Myc suppression in MCF-7 and A549 cells. J Ethnopharmacol 2012, 141:803-809.
17. Thangam R., Kannan S., Suresh B., et al. Overexpression of cyclooxygenase 2 detected in MCF-7 breast cancer cell and compared with lung carcinoma cell line. IJBMR 2011, 2:320-333.
18. Thangam R., Gunasekaran P., Kaveri K., et al. A novel disintegrin protein from Naja naja venom induces cytotoxicity and apoptosis in human cancer cell lines in vitro. Process Biochem 2012, 47:1243-1249.
19. Eymin B., Gazzeri S., Brambilla C., et al. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene 2001, 20:1678-1687.
20. Salon C., Eymin B., Micheau O., et al. E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP (short). Cell Death Differ 2006, 13:260-272.
21. Hurst C.D., Fiegler H., Carr P., et al. High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene 2004, 23:2250-2263.
22. Aaboe M., Birkenkamp-Demtroder K., Wiuf C., et al. SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res 2006, 66:3434-3442.
23. Oeggerli M., Schraml P., Ruiz C., et al. E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. Oncogene 2006, 25:6538-6543.
24. Coe B.P., Lockwood W.W., Girard L., et al. Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer. Br J Cancer 2006, 94:1927-1935.
25. Hurst C.D., Darren C., Sarah V., et al. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. Oncogene 2008, 24(27):2716-2727.
26. Richter J., Wagner U., Kononen J., et al. High throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000, 157:787-794.